Press Release 2018

Press Release 2018

NigellinTM Amber, Pearl and Onyx Black Cumin Seed Featured

Sabinsa will launch ShagandhaTM USP grade branded Ashwagandha at SupplySide West, November 8-9, 2018 in Las Vegas, with experts on hand to describe why Sabinsa’s distinctive extract will change the way people look at this popular adaptogen.

shaganda

The company will also showcase three versions of the recently introduced NigellinTm, Sabinsa’s standardized Black Cumin (Nigella sativa) Seed extract, in Amber, Onyx and Pearl editions. This emerging antioxidant ingredient has traditionally been used in the management of several health conditions, with recent research beginning to validate historically reported benefits.

As SupplySide West is the final major trade show of 2018, Sabinsa will host the last celebration of their 30th anniversary year with champagne in the booth at 4:00 PM on November 8, the first day of the show.

 

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.